Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$37.71 -1.2%	$37.21	$23.42 ▼ $62.58	$2.19B	0.87	844,455 shs	502,787 shs
ALVO Alvotech	$8.07 +0.2%	$8.76	$7.35 ▼ $13.70	$2.43B	0.1	487,703 shs	229,923 shs
ELTP Elite Pharmaceuticals	$0.69 +4.1%	$0.58	$0.25 ▼ $0.82	$734.61M	0.25	1.99 million shs	7.56 million shs
OGN Organon & Co.	$9.40 +2.3%	$9.60	$8.01 ▼ $22.67	$2.45B	0.6	4.81 million shs	4.58 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+1.21%	+7.74%	+13.01%	-17.86%
ALVO Alvotech	0.00%	-3.00%	-8.19%	-29.52%	-30.91%
ELTP Elite Pharmaceuticals	0.00%	+23.63%	+41.27%	+27.08%	+147.97%
OGN Organon & Co.	0.00%	+3.53%	-3.74%	-0.42%	-57.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.42 of 5 stars	3.4	2.0	0.0	4.3	4.2	0.8	1.9
ALVO Alvotech	3.4674 of 5 stars	3.3	4.0	0.0	0.0	2.4	0.0	1.9
ELTP Elite Pharmaceuticals	0.0991 of 5 stars	0.0	3.0	0.0	0.0	0.6	0.8	0.0
OGN Organon & Co.	4.7532 of 5 stars	3.3	2.0	1.7	3.7	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	49.39% Upside
ALVO Alvotech	2.50	Moderate Buy	$14.00	73.48% Upside
ELTP Elite Pharmaceuticals	0.00	N/A	N/A	N/A
OGN Organon & Co.	2.50	Moderate Buy	$18.00	91.59% Upside

Current Analyst Ratings Breakdown

Latest ELTP, ALVO, OGN, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALVO Alvotech	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	60.03	N/A	N/A	$27.02 per share	1.40
ALVO Alvotech	$491.98M	4.95	N/A	N/A	($1.37) per share	-5.89
ELTP Elite Pharmaceuticals	$84.04M	8.74	$0.02 per share	39.99	$0.05 per share	13.72
OGN Organon & Co.	$6.40B	0.38	$4.92 per share	1.91	$1.83 per share	5.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.43	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
ALVO Alvotech	-$231.86M	$0.23	35.09	40.35	N/A	11.26%	-38.36%	9.28%	11/12/2025 (Estimated)
ELTP Elite Pharmaceuticals	-$4.32M	-$0.01	N/A	∞	N/A	-10.26%	-9.88%	-4.72%	11/13/2025 (Estimated)
OGN Organon & Co.	$864M	$2.69	3.49	2.51	0.86	11.15%	163.88%	6.99%	10/30/2025 (Estimated)

Latest ELTP, ALVO, OGN, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	ELTP Elite Pharmaceuticals	N/A	-$0.01	N/A	-$0.01	N/A	$40.21 million
8/13/2025	Q2 2025	ALVO Alvotech	-$0.26	$0.14	+$0.40	$0.14	$120.51 million	$116.02 million
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million
6/30/2025	Q4 2025	ELTP Elite Pharmaceuticals	N/A	$0.01	N/A	$0.02	N/A	$32.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
ELTP Elite Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.97%	N/A

Latest ELTP, ALVO, OGN, and AGIO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/5/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
ALVO Alvotech	N/A	1.82	1.27
ELTP Elite Pharmaceuticals	0.09	7.23	5.44
OGN Organon & Co.	11.98	1.65	1.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ALVO Alvotech	N/A
ELTP Elite Pharmaceuticals	0.01%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
ALVO Alvotech	N/A
ELTP Elite Pharmaceuticals	14.42%
OGN Organon & Co.	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
ALVO Alvotech	1,032	301.48 million	N/A	Not Optionable
ELTP Elite Pharmaceuticals	40	1.07 billion	916.45 million	Not Optionable
OGN Organon & Co.	4,000	259.97 million	256.33 million	Not Optionable

ELTP, ALVO, OGN, and AGIO Headlines

Recent News About These Companies

Head-To-Head Comparison: Organon & Co. (NYSE:OGN) vs. DocGo (NASDAQ:DCGO)

August 31 at 2:31 AM | americanbankingnews.com

Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio

August 29, 2025 | finance.yahoo.com

Deutsche Bank AG Has $1.06 Million Holdings in Organon & Co. $OGN

August 27, 2025 | marketbeat.com

Orogen Royalties Reports Q2 2025 Financial Results Based on Carve-out Financial Statements

August 26, 2025 | accessnewswire.comA

Quantbot Technologies LP Takes Position in Organon & Co. $OGN

August 26, 2025 | marketbeat.com

589,186 Shares in Organon & Co. $OGN Acquired by Nuveen LLC

August 26, 2025 | marketbeat.com

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

August 25, 2025 | zacks.com

Algert Global LLC Acquires New Stake in Organon & Co. $OGN

August 23, 2025 | marketbeat.com

Invesco Ltd. Has $28.85 Million Position in Organon & Co. $OGN

August 22, 2025 | marketbeat.com

Organon & Co. (NYSE:OGN) Shares Sold by Brandywine Global Investment Management LLC

August 18, 2025 | marketbeat.com

Russell Investments Group Ltd. Sells 128,059 Shares of Organon & Co. (NYSE:OGN)

August 18, 2025 | marketbeat.com

Vanguard Group Inc. Sells 699,976 Shares of Organon & Co. (NYSE:OGN)

August 17, 2025 | marketbeat.com

Organon & Co. (NYSE:OGN) Shares Purchased by KLCM Advisors Inc.

August 16, 2025 | marketbeat.com

There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings

August 15, 2025 | finance.yahoo.com

LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN)

August 15, 2025 | marketbeat.com

Public Sector Pension Investment Board Has $12.16 Million Position in Organon & Co. (NYSE:OGN)

August 14, 2025 | marketbeat.com

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

August 13, 2025 | prnewswire.com

Organon: Valuation Discount Offset By Structural Headwinds

August 12, 2025 | seekingalpha.com

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

August 12, 2025 | zacks.com

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend

August 11, 2025 | finance.yahoo.com

OGN vs. HQY: Which Stock Is the Better Value Option?

August 8, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELTP, ALVO, OGN, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$37.71 -0.47 (-1.23%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$37.72 +0.02 (+0.04%)

As of 08/29/2025 05:38 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alvotech NASDAQ:ALVO

$8.07 +0.02 (+0.25%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.07 0.00 (0.00%)

As of 08/29/2025 04:10 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Elite Pharmaceuticals OTCMKTS:ELTP

$0.69 +0.03 (+4.13%)

As of 08/29/2025 03:59 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Organon & Co. NYSE:OGN

$9.40 +0.22 (+2.34%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$9.43 +0.03 (+0.32%)

As of 08/29/2025 06:52 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time